- Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Motzer, R.J., Rakhit, A., Thompson, J., Gurney, H., Selby, P., Figlin, R., Negrier, S., Ernst, S., Siebels, M., Ginsberg, M., Rittweger, K., Hooftman, L. Ann. Oncol. (2002)